Has India’s ‘Covishield’ Vaccine Manufacturer Confirmed Its Availability in 73 Days?

Reports circulating online claim that India’s vaccine manufacturer, the Serum Institute of India (SII), has confirmed the availability of its ‘Covishield’ COVID-19 vaccine in 73 days. The claim has been published by news websites such as India Today, Business Today, You News, North East Now and LatestLY.


Trials are currently underway for a COVID-19 vaccine developed by Oxford University in partnership with Swedish-British drugs producer AstraZeneca. According to Oxford University, the vaccine is in phase 3, which is meant to prove that the vaccine will prevent people from the virus.

The Serum Institute of India is in charge of conducting clinical trials of the vaccine in India, where the vaccine is dubbed ‘Covishield’.

Information on the SII website indicates that the institute, on July 31, got an approval to start human trials of the vaccine in India. SII CEO Adar Poonawalla in a tweet, said that he hopes to get positive results from the phase 3 trials.


SII on August 23 issued a statement disputing claims that it had announced the availability of the ‘Covishield’ vaccine.

The statement published on the institution’s Facebook and Twitter accounts termed the claims as misleading since the vaccine is currently under trials.

“Presently, the government has granted us permission to only manufacture the vaccine and stockpile it for future use,” reads SII’s Facebook statement.

“COVISHIELD will be commercialised once the trials are proven successful and all the requisite regulatory approvals are in place,” the statement adds.


Claims that the Covishield vaccine will be available for use in 73 days are FALSE.

Add comment

Your email address will not be published. Required fields are marked *